scholarly journals Edema Surrounding Benign Tumors and Tumor-Like Lesions

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Sai Gao ◽  
Ruizhi Zhou ◽  
Qi Xu ◽  
Haisong Chen
Keyword(s):  
Bone Marrow ◽  
Soft Tissue ◽  
Incidence Rate ◽  
Osteoid Osteoma ◽  
Langerhans Cell Histiocytosis ◽  
Malignant Tumors ◽  
Langerhans Cell ◽  
Common Finding ◽  
Benign Tumors ◽  
Tissue Edema

Objective. To explore the incidence and significance of intra- and extra-osseous edema associated with benign tumors and tumor-like diseases. Methods. Magnetic resonance imaging (MRI) data from 300 benign osseous tumors and tumor-like diseases diagnosed by pathology were retrospectively reviewed. Borderline tumors, cases associated with pathological fractures, and skull lesions were excluded from the study. Bone marrow and soft tissue edema were defined on T2WI with fat suppression on MRI in all cases. The incidence rate of edema in benign tumors and tumor-like diseases was determined using the χ2 test. The preoperative diagnoses were reviewed, and the effect of edema on the differential diagnosis of benign and malignant tumors was analyzed. Results. The incidence rate of bone marrow and soft tissue edema associated with benign tumors and tumor-like diseases was 35.7% (107/300), including 84.4% (27/32) Langerhans cell histiocytosis, 86.4% (19/22) osteoblastoma, 93.9% (31/33) osteoid osteoma, and 85.2% (23/27) chondroblastoma cases. There was no statistically significant difference in the incidence of edema among the four diseases (χ2=1.7, P>0.05). Of 107 cases associated with edema, 49 (45.8%) were misdiagnosed as malignant tumors by MRI preoperatively. Conclusion. Bone marrow and soft tissue edema are a common finding associated with benign bone tumors and tumor-like diseases, and they are frequently detected in Langerhans cell histiocytosis, osteoblastoma, osteoid osteoma, and chondroblastoma.

Multifocal soft tissue Langerhans’ cell histiocytosis treated with PET-CT based conformal radiotherapy

2015 ◽  
Vol 33 (9) ◽  
pp. 603-606
Author(s):  
Cem Onal ◽  
Ezgi Oymak ◽  
Mehmet Reyhan ◽  
Tuba Canpolat ◽  
Ozgur Ozyilkan
Keyword(s):  
Soft Tissue ◽  
Langerhans Cell Histiocytosis ◽  
Conformal Radiotherapy ◽  
Langerhans Cell ◽  
Pet Ct

scholarly journals Histopathological study of soft tissue tumours in a tertiary health centre in southern part of Assam

2021 ◽  
Vol 9 (11) ◽  
pp. 3391
Author(s):  
Khadija S. Tapadar ◽  
Manoj K. Deka ◽  
R. N. Chaubey ◽  
Shah A. Sheikh ◽  
Gargi R. Choudhury ◽  
...  
Keyword(s):  
Soft Tissue ◽  
Malignant Tumors ◽  
Soft Tissue Tumors ◽  
The Body ◽  
World Health ◽  
Vascular Tumors ◽  
Benign Tumors ◽  
Peripheral Nerve Sheath Tumors ◽  
Pleomorphic Sarcoma ◽  
Younger Age

Background: Soft tissue tumors are defined as mesenchymal proliferations which occur in the extraskeletal non-epithelial tissues of the body, excluding the viscera, coverings of brain and   lymphoreticular system. The objective of this study was to study the histopathological features of soft tissue tumors and to study the occurrence of soft tissue tumors in relation to age, sex and anatomical site.Methods: This study comprised of 89 cases studied over a period of two years. All soft tissue tumors, their gross features, microscopic findings were analysed in detail. Soft tissue tumors were divided into benign and malignant categories and further sub typing were done according to World Health Organization (WHO) classification. The distribution of soft tissue tumors according to the age, sex and site of occurrence was studied.Results: Out of 89 cases of soft tissue tumors, 76 cases were benign, 4 cases belonged to intermediate category and 9 cases were malignant. Adipocytic tumors formed the largest group constituting 39 cases. Vascular tumors were the second commonest (26 cases) followed by peripheral nerve sheath tumors (11 cases). The benign tumors were seen in younger age as compared to malignant tumors. Malignant soft tissue tumors was seen to be more common in male than female and pleomorphic sarcoma and liposarcoma was commonest (3 cases each).Conclusions: Benign tumors were more common than malignant. The most common benign tumors were lipoma followed by hemangioma and schwannoma. The most common malignant tumor was pleomorphic sarcoma. The benign tumors were seen in younger age as compared to malignant tumors.

scholarly journals AN UNUSUAL PRESENTATION OF LANGERHANS CELL HISTIOCYTOSIS

2012 ◽  
Vol 02 (04) ◽  
pp. 77-79
Author(s):  
Jayaprakash Shetty K. ◽  
Ajith Kumar ◽  
Shantharam Shetty ◽  
Kishan Prasad H. L. ◽  
Chandrika Rao
Keyword(s):  
Langerhans Cell Histiocytosis ◽  
Malignant Tumors ◽  
Histopathological Examination ◽  
Eosinophilic Granuloma ◽  
Langerhans Cell ◽  
Lytic Lesion ◽  
Unknown Aetiology ◽  
Diagnostic Challenge ◽  
Osseous Involvement ◽  
Common Manifestation

AbstractLangerhans cell histiocytosis most commonly occurring in children, demonstrates a broad spectrum of clinical and radiologic features that may mimic those of infection as well as benign and malignant tumors. Osseous involvement is the most common manifestation. Recognition of the skeletal alterations is important so that the disease is considered as differential diagnosis. This disease is of unknown aetiology, non-specific clinical and imaging findings with diagnosis possible only on histopathological examination, will always pose a diagnostic challenge to the orthopaedic surgeon. Here by we are reporting two cases of eosinophilic granuloma that has presented with lytic lesion in the tibia and scapula. The clinico-radiological suspicion was either infection or tumour of the affected bones. Hence, core biopsy was done confirmed as eosinophilic granuloma on histopathology and immunohistochemistry.

scholarly journals Hematopoietic origin of Langerhans cell histiocytosis and Erdheim-Chester disease in adults

Blood ◽  
2017 ◽  
Vol 130 (2) ◽  
pp. 167-175 ◽  
Author(s):  
Paul Milne ◽  
Venetia Bigley ◽  
Chris M. Bacon ◽  
Antoine Néel ◽  
Naomi McGovern ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Langerhans Cell Histiocytosis ◽  
Mutant Allele ◽  
Langerhans Cell ◽  
Macrophage Differentiation ◽  
Allele Distribution ◽  
Key Points ◽  
Erdheim Chester ◽  
Disease Specific ◽  
Chester Disease

Key Points Bone marrow progenitors, monocytes, and myeloid DCs contain BRAFV600E alleles in adults with LCH and ECD. Mutant allele distribution is not disease specific, but precursors have distinct LCH-like and macrophage differentiation capacities.

Treatment of a Patient with Refractory Non-Langerhans-Cell-Histiocytosis with the Tyrosine Kinase Inhibitor Sorafenib: Clinical and Genetic Implications

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 4715-4715
Author(s):  
Andreas Viardot ◽  
Frank Stegelmann ◽  
Thorsten Zenz ◽  
Peter Möller ◽  
Konstanze Döhner
Keyword(s):  
Bone Marrow ◽  
Tyrosine Kinase ◽  
Langerhans Cell Histiocytosis ◽  
Kinase Inhibitor ◽  
Langerhans Cell ◽  
Braf V600e ◽  
Off Label Use ◽  
Off Label ◽  
Hands And Feet ◽  
Label Use

Abstract Abstract 4715 Non-Langerhans-cell-histiocytosis (Non-LCH) represents a rare disorder with a broad spectrum of clinical features and various outcome. We here report on a 61 years old man with Non-LCH with severe skin and bone marrow involvement. At the time of diagnosis in 2006, the patient presented with up to four centimeter large cutaneous papules involving face, stem, hands and feet. Since two years, the patient also developed an increasing tricytopenia due to an extensive bone marrow infiltration of histiocytes (80%). Since diagnosis, the patient received a large number of various therapies including daily glucocorticoids at different dosages (continuously since diagnosis), low-dose methotrexate (10-40mg s.c. per week; from may to september 2007), experimental treatment with lenalidomide (5-10mg per day; from february to june 2008), continous oral trofosfamide (100mg per day; from july to august 2008), cladribine monotherapy (2,1mg/m2 d1-5; 4 cycles; from December 2008 to march 2009) and the combination of cladribine (2.1mg/m2 d1-5) and cytarabine (40 mg s.c. d1-7; 3 cycles; from january to march 2010). The patient did not respond to any of these therapies. Due to the persistent distinctive clinical symptoms (massive skin involvement, tricytopenia), we started in July 2010 an experimental therapy with sorafenib at a dosage of 200mg per day for four days, followed by 400mg per day for another four days, and subsequently increased the dosage to 800mg daily. After four weeks, the marked skin papules flattened to skin level at all preferential sites. Small skin ulcers at the cheeks healed up. In parallel, there was a significant improvement of hematopoiesis since start of therapy with haemoglobin levels raising from 8,6g/dl to 12,2g/dl and normalization of leukocyte count (from 3.1/nl to 5.2/nl). Bone marrow rebiopsy is intended after three month of therapy, data on the actual grade of infiltration will be presented at the meeting. Based on the impressive clinical improvement under sorafenib, we analyzed selected target genes of the multityrosine kinase inhibitor: mutation screening was performed on the FLT3 (internal tandem duplication, point mutations of the tyrosine kinase domain) and KIT genes (exon 8 and exon 17) as well as for the recently described BRAF V600E mutation found in a significant number of patients with LCH (G. Badalian-Very et al., Blood prepublished online June 2, 2010; DOI 10.1182/blood-2010-04-279083). However, in none of these genes, mutations were found and further molecular analysis of the patient's bone marrow is currently under investigation. To our knowledge, this is the first report on the efficacy of sorafenib in a case of histiocytosis. However, the underlying genetic mechanisms of Non-LCH still have to be elucidated. Disclosures: Off Label Use: Sorafenib is approved for unresectable hepatocellular carcinoma and advanced renal cancer. We present an off-label use of sorafenib in a case of a severe orphan disease refractory to all standard therapies. Zenz:Roche: Honoraria; Boehringer: Honoraria; GSK: Honoraria; Celgene: Honoraria.

scholarly journals Otic Langerhans' Cell Histiocytosis in an Adult: A Case Report and Review of the Literature

2013 ◽  
Vol 2013 ◽  
pp. 1-3
Author(s):  
Anil Gungadeen ◽  
Peter Kullar ◽  
Philip Yates
Keyword(s):  
Case Report ◽  
Soft Tissue ◽  
Systemic Therapy ◽  
Langerhans Cell Histiocytosis ◽  
Relevant Literature ◽  
Langerhans Cell ◽  
Tissue Mass ◽  
Bony Lesions ◽  
Soft Tissue Masses ◽  
Ear Symptoms

Objective. To present a case of otic Langerhans' cell histiocytosis in an adult. Also included the diagnosis and management of the condition and a review of the relevant literature.Case Report. We report a case of a 41-year-old man with a history of persistent unilateral ear discharge associated with an aural polyp. Radiological imaging showed bony lesions of the skull and a soft-tissue mass within the middle ear. Histological analysis of the polyp demonstrated Langerhans' cell histiocytosis. His otological symptoms were completely resolved with the systemic therapy.Conclusions. Otic Langerhans' cell histiocytosis can present in adults. Persistent ear symptoms along with evidence of soft-tissue masses within the ear and bony lesions of the skull or elsewhere should prompt the otolaryngologists to include Langerhans' cell histiocytosis in their differential diagnosis. Management should be with systemic therapy rather than local surgical treatment.

Sign in / Sign up

Export Citation Format

Share Document